Compare ATON & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATON | EDSA |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | British Virgin Islands | Canada |
| Employees | 4 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 7.5M |
| IPO Year | N/A | 2018 |
| Metric | ATON | EDSA |
|---|---|---|
| Price | $0.33 | $7.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 763.1K | 315.9K |
| Earning Date | 07-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.72 |
| 52 Week High | $13.80 | $9.37 |
| Indicator | ATON | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 62.63 |
| Support Level | $0.28 | $1.41 |
| Resistance Level | $0.35 | $9.06 |
| Average True Range (ATR) | 0.03 | 0.73 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 71.54 | 83.74 |
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.